CY1124184T1 - Σχηματα δοσολογιας της αμισουλπριδης για τη θεραπεια της ναυτιας και του εμετου - Google Patents
Σχηματα δοσολογιας της αμισουλπριδης για τη θεραπεια της ναυτιας και του εμετουInfo
- Publication number
- CY1124184T1 CY1124184T1 CY20211100442T CY211100442T CY1124184T1 CY 1124184 T1 CY1124184 T1 CY 1124184T1 CY 20211100442 T CY20211100442 T CY 20211100442T CY 211100442 T CY211100442 T CY 211100442T CY 1124184 T1 CY1124184 T1 CY 1124184T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amisulpride
- vomiting
- nausea
- chemotherapy
- day
- Prior art date
Links
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 title abstract 6
- 229960003036 amisulpride Drugs 0.000 title abstract 6
- 206010047700 Vomiting Diseases 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 abstract 4
- 238000002512 chemotherapy Methods 0.000 abstract 3
- 206010028813 Nausea Diseases 0.000 abstract 2
- 230000003474 anti-emetic effect Effects 0.000 abstract 2
- 239000002111 antiemetic agent Substances 0.000 abstract 2
- 230000008693 nausea Effects 0.000 abstract 2
- 230000008673 vomiting Effects 0.000 abstract 2
- 239000007972 injectable composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506116.1A GB201506116D0 (en) | 2015-04-10 | 2015-04-10 | Kit and combination therapy for nausea and vomiting |
| PCT/GB2016/050998 WO2016162695A1 (en) | 2015-04-10 | 2016-04-11 | Combinations of amisulpride and another anti-emetic for treating nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124184T1 true CY1124184T1 (el) | 2022-07-22 |
Family
ID=53333601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100442T CY1124184T1 (el) | 2015-04-10 | 2021-05-20 | Σχηματα δοσολογιας της αμισουλπριδης για τη θεραπεια της ναυτιας και του εμετου |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10322106B2 (enExample) |
| EP (1) | EP3280392B1 (enExample) |
| JP (1) | JP6812360B2 (enExample) |
| KR (2) | KR20240125705A (enExample) |
| CN (1) | CN107872975A (enExample) |
| AU (1) | AU2016246104B2 (enExample) |
| CA (1) | CA2982251C (enExample) |
| CY (1) | CY1124184T1 (enExample) |
| DK (1) | DK3280392T3 (enExample) |
| ES (1) | ES2866933T3 (enExample) |
| GB (1) | GB201506116D0 (enExample) |
| HR (1) | HRP20210624T1 (enExample) |
| HU (1) | HUE054165T2 (enExample) |
| IL (2) | IL295650A (enExample) |
| LT (1) | LT3280392T (enExample) |
| MX (1) | MX388735B (enExample) |
| PL (1) | PL3280392T3 (enExample) |
| PT (1) | PT3280392T (enExample) |
| RS (1) | RS61760B1 (enExample) |
| SI (1) | SI3280392T1 (enExample) |
| SM (1) | SMT202100216T1 (enExample) |
| WO (1) | WO2016162695A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| KR20200110317A (ko) | 2017-12-05 | 2020-09-23 | 선오비온 파마슈티컬스 인코포레이티드 | 결정형 및 이의 제조 방법 |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| EP4496797A1 (en) | 2022-03-21 | 2025-01-29 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN120693338A (zh) | 2022-12-22 | 2025-09-23 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| IL322686A (en) | 2023-02-16 | 2025-10-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| TW202521528A (zh) | 2023-07-13 | 2025-06-01 | 美商雅空嘉閣生物公司 | 化合物、組合物及方法 |
| AR133241A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003962D0 (en) | 2010-03-10 | 2010-04-21 | Tangentix Ltd | Multimedia content delivery system |
| GB201004020D0 (en) * | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| US20150018360A1 (en) * | 2011-09-13 | 2015-01-15 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating metabolic disorders |
-
2015
- 2015-04-10 GB GBGB1506116.1A patent/GB201506116D0/en not_active Ceased
-
2016
- 2016-04-11 PL PL16716659T patent/PL3280392T3/pl unknown
- 2016-04-11 CA CA2982251A patent/CA2982251C/en active Active
- 2016-04-11 CN CN201680030994.9A patent/CN107872975A/zh active Pending
- 2016-04-11 SI SI201631183T patent/SI3280392T1/sl unknown
- 2016-04-11 SM SM20210216T patent/SMT202100216T1/it unknown
- 2016-04-11 MX MX2017012991A patent/MX388735B/es unknown
- 2016-04-11 ES ES16716659T patent/ES2866933T3/es active Active
- 2016-04-11 LT LTEP16716659.4T patent/LT3280392T/lt unknown
- 2016-04-11 PT PT167166594T patent/PT3280392T/pt unknown
- 2016-04-11 WO PCT/GB2016/050998 patent/WO2016162695A1/en not_active Ceased
- 2016-04-11 DK DK16716659.4T patent/DK3280392T3/da active
- 2016-04-11 HU HUE16716659A patent/HUE054165T2/hu unknown
- 2016-04-11 IL IL295650A patent/IL295650A/en unknown
- 2016-04-11 JP JP2017553076A patent/JP6812360B2/ja active Active
- 2016-04-11 KR KR1020247026775A patent/KR20240125705A/ko active Pending
- 2016-04-11 HR HRP20210624TT patent/HRP20210624T1/hr unknown
- 2016-04-11 US US15/565,479 patent/US10322106B2/en active Active
- 2016-04-11 KR KR1020177032393A patent/KR102711661B1/ko active Active
- 2016-04-11 RS RS20210407A patent/RS61760B1/sr unknown
- 2016-04-11 EP EP16716659.4A patent/EP3280392B1/en active Active
- 2016-04-11 AU AU2016246104A patent/AU2016246104B2/en active Active
-
2017
- 2017-10-08 IL IL254929A patent/IL254929A0/en unknown
-
2021
- 2021-05-20 CY CY20211100442T patent/CY1124184T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3280392T3 (da) | 2021-03-08 |
| MX388735B (es) | 2025-03-20 |
| CA2982251C (en) | 2023-06-13 |
| EP3280392A1 (en) | 2018-02-14 |
| IL295650A (en) | 2022-10-01 |
| KR102711661B1 (ko) | 2024-10-02 |
| KR20180016350A (ko) | 2018-02-14 |
| US10322106B2 (en) | 2019-06-18 |
| WO2016162695A1 (en) | 2016-10-13 |
| IL254929A0 (en) | 2017-12-31 |
| AU2016246104A1 (en) | 2017-11-30 |
| GB201506116D0 (en) | 2015-05-27 |
| US20180071249A1 (en) | 2018-03-15 |
| JP2018510898A (ja) | 2018-04-19 |
| JP6812360B2 (ja) | 2021-01-13 |
| MX2017012991A (es) | 2018-02-01 |
| PT3280392T (pt) | 2021-03-12 |
| RS61760B1 (sr) | 2021-05-31 |
| PL3280392T3 (pl) | 2021-10-18 |
| LT3280392T (lt) | 2021-04-26 |
| HUE054165T2 (hu) | 2021-08-30 |
| AU2016246104B2 (en) | 2018-12-13 |
| KR20240125705A (ko) | 2024-08-19 |
| EP3280392B1 (en) | 2021-02-24 |
| SI3280392T1 (sl) | 2021-08-31 |
| HK1250913A1 (en) | 2019-01-18 |
| CA2982251A1 (en) | 2016-10-13 |
| CN107872975A (zh) | 2018-04-03 |
| ES2866933T3 (es) | 2021-10-20 |
| HRP20210624T1 (hr) | 2021-05-28 |
| SMT202100216T1 (it) | 2021-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124184T1 (el) | Σχηματα δοσολογιας της αμισουλπριδης για τη θεραπεια της ναυτιας και του εμετου | |
| CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| CL2020003174S1 (es) | Dispositivo para administración de dosis. | |
| MX2019008028A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1). | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2021009222A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1). | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| MX2018013827A (es) | Sistema y metodo de dosificacion radiologica. | |
| CO2020008825A2 (es) | Regímenes de dosificación superior de g1t38 | |
| MX2020012755A (es) | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). | |
| CR20220355A (es) | Compuestos activos frente a receptores nucleares | |
| CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| MX390755B (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| ECSP18060820A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano | |
| CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| CY1124580T1 (el) | Φαρμακευτικα σκευασματα που περιλαμβανουν παραγωγα φαινυλαμινοπυριμιδινης | |
| CO2019015102A2 (es) | Nuevos derivados de xantina sustituidos | |
| JOP20210051A1 (ar) | علاج للسرطان بواسطة استخدم توليفة من فيروس الوقس الحال للورم ومثبط نقاط الفحص المناعي، وتركيبة صيدلانية ودواء توليفي للاستخدام في علاج السرطان | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CO2022004947A2 (es) | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente |